Showing posts with label hepatitis C virus (HCV) NS3/4A protease inhibitor. Show all posts
Showing posts with label hepatitis C virus (HCV) NS3/4A protease inhibitor. Show all posts

Thursday, January 1, 2015

FDA Approves Olysio (simeprevir) in Combination with Sofosbuvir for Genotype 1 Chronic Hepatitis C Infection


Sofosbuvir.svgSimeprevir.svg

In continuation of my update on Sofosbuvir (left) and  Simeprevir (right)

Janssen Therapeutics, Division of Janssen Products, LP (Janssen) announced the U.S. Food and Drug Administration (FDA) has approved Olysio (simeprevir), a hepatitis C virus (HCV) NS3/4A protease inhibitor, in combination with sofosbuvir as an all-oral, interferon- and ribavirin-free treatment option for genotype 1 chronic hepatitis C (CHC) infection in adult patients as part of a combination antiviral treatment regimen. Sofosbuvir is an HCV nucleotide analog NS5B polymerase inhibitor developed by Gilead Sciences, Inc.